{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:20:33Z","timestamp":1790169633024,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40290-026-00620-2","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T17:28:55Z","timestamp":1786382935000},"page":"351-356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrated Evidence Generation Planning: Why Medical Affairs is a Critical Partner"],"prefix":"10.1007","volume":"40","author":[{"given":"Ronaldo","family":"Fujii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucija","family":"Fleisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Male","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1997-3705","authenticated-orcid":false,"given":"Antonia","family":"Panayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"620_CR1","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMsb1610128","volume":"375","author":"RM Califf","year":"2016","unstructured":"Califf RM, Robb MA, Bindman AB, Briggs JP, Collins FS, Conway PH, et al. Transforming evidence generation to support health and health care decisions. N Engl J Med. 2016;375:2395\u2013400. https:\/\/doi.org\/10.1056\/NEJMsb1610128.","journal-title":"N Engl J Med"},{"key":"620_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.12688\/f1000research.13585.2","volume":"7","author":"S Khosla","year":"2018","unstructured":"Khosla S, White R, Medina J, Ouwens M, Emmas C, Koder T, et al. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation? F1000Res. 2018;7:111. https:\/\/doi.org\/10.12688\/f1000research.13585.2.","journal-title":"F1000Res"},{"key":"620_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/cer-2017-0073","volume":"7","author":"MS Olson","year":"2018","unstructured":"Olson MS. Developing an integrated strategy for evidence generation. J Comp Eff Res. 2018;7:5\u20139. https:\/\/doi.org\/10.2217\/cer-2017-0073.","journal-title":"J Comp Eff Res"},{"key":"620_CR4","unstructured":"Grueger N, Andre N, Vaidyanathan S. The future of integrated evidence planning in biopharma. 2023. https:\/\/www.bcg.com\/publications\/2023\/the-future-of-integrated-evidence-planning-in-biopharma#:~:text=Biopharma%20functions%20are%20responsible%20for,needs%20of%20multiple%20stakeholder%20groups. Accessed 30 Jan 2025."},{"key":"620_CR5","unstructured":"Amin P, Nam S, Perez L, Smith J. Integrated evidence generation: A paradigm shift in biopharma. 2021. https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/integrated-evidence-generation-a-paradigm-shift-in-biopharma. Accessed 30 Jan 2025."},{"key":"620_CR6","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022;12:3049\u201362. https:\/\/doi.org\/10.1016\/j.apsb.2022.02.002.","journal-title":"Acta Pharm Sin B"},{"key":"620_CR7","doi-asserted-by":"publisher","unstructured":"Nelissen J WA, James C, Male G. Empowering Medical Affairs professionals in their critical role in integrated evidence generation planning. Pharmaceutical Medicine. 2026. https:\/\/doi.org\/10.1007\/s40290-026-00625-x.","DOI":"10.1007\/s40290-026-00625-x"},{"key":"620_CR8","volume-title":"Clinical epidemiology: how to do clinical practice research","author":"RB Haynes","year":"2005","unstructured":"Haynes RB, Sackett DL, Guyatt GH, Tugwell P. Clinical epidemiology: how to do clinical practice research. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2005.","edition":"3rd ed"},{"key":"620_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/cpt.2466","volume":"111","author":"NM Gatto","year":"2022","unstructured":"Gatto NM, Campbell UB, Rubinstein E, Jaksa A, Mattox P, Mo J, et al. The structured process to identify fit-for-purpose data: a data feasibility assessment framework. Clin Pharmacol Ther. 2022;111:122\u201334. https:\/\/doi.org\/10.1002\/cpt.2466.","journal-title":"Clin Pharmacol Ther"},{"key":"620_CR10","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1080\/03007995.2023.2263353","volume":"39","author":"R White","year":"2023","unstructured":"White R. Building trust in real world evidence (RWE): moving transparency in RWE towards the randomized controlled trial standard. Curr Med Res Opin. 2023;39:1737\u201341. https:\/\/doi.org\/10.1080\/03007995.2023.2263353.","journal-title":"Curr Med Res Opin"},{"key":"620_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/cer-2016-0070","volume":"6","author":"R White","year":"2017","unstructured":"White R. Building trust in real-world evidence and comparative effectiveness research: the need for transparency. J Comp Eff Res. 2017;6:5\u20137. https:\/\/doi.org\/10.2217\/cer-2016-0070.","journal-title":"J Comp Eff Res"},{"key":"620_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-015-0028-2","volume":"16","author":"FX Liu","year":"2015","unstructured":"Liu FX, Rutherford P, Smoyer-Tomic K, Prichard S, Laplante S. A global overview of renal registries: a systematic review. BMC Nephrol. 2015;16:31. https:\/\/doi.org\/10.1186\/s12882-015-0028-2.","journal-title":"BMC Nephrol"},{"key":"620_CR13","unstructured":"European Commission. Joint Scientific Consultations. https:\/\/health.ec.europa.eu\/health-technology-assessment\/implementation-regulation-health-technology-assessment\/joint-scientific-consultations_en. Accessed 30 Jan 2025."},{"key":"620_CR14","unstructured":"European Commission. Joint Clinical Assessment for Medicinal Products. https:\/\/health.ec.europa.eu\/document\/download\/ced91156-ffe1-472d-85eb-aa6a91dd707e_en?filename=hta_htar_factsheet-jca_en.pdf. Accessed 30 Jan 2025."},{"key":"620_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy11060187","volume":"11","author":"C Lieneck","year":"2022","unstructured":"Lieneck C, McLauchlan M, Adachi V, Billings R. Stakeholder perspectives of the Inflation Reduction Act\u2019s (2022) impact on prescription drugs: a narrative review. Pharmacy (Basel). 2022;11:187. https:\/\/doi.org\/10.3390\/pharmacy11060187.","journal-title":"Pharmacy (Basel)"},{"key":"620_CR16","unstructured":"The Evidence Base. Infographic: Inflation Reduction Act in numbers. https:\/\/www.evidencebaseonline.com\/infographics\/infographic-inflation-reduction-act-in-numbers\/. Accessed 30 Jan 2025."}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00620-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-026-00620-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00620-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:22:50Z","timestamp":1788495770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-026-00620-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["620"],"URL":"https:\/\/doi.org\/10.1007\/s40290-026-00620-2","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"18 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ronaldo Fujii, Masoud Nouri, Mohammad Khan and Antonia Panayi are employees of Takeda Development Center Americas, Inc. and report holding stock and stock options in this company. Jamie Pugh and Gary Male are employees of Oxford PharmaGenesis Ltd. Lucija Fleisinger was an employee of Oxford PharmaGenesis Ltd at the time of manuscript development and review.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the outline and subsequent drafts of this manuscript. All authors contributed to the drafting and critical review of the manuscript content and approved the final manuscript.","order":2,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No data were generated or analyzed during development of this review. All information supporting this review is derived from previously published studies and their respective sources.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}